{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-002761","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.212802+00:00","generated_at":"2026-06-20T07:24:06.624260+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"ZyVersa grants 100,000-share option inducement to new CMO Dr. Pablo Guzman at $2.11","bullets":["Nonqualified stock option to purchase 100,000 shares at $2.11/share, the Jan 25, 2023 closing price.","Option has 10-year term, vests in three equal annual installments starting Jan 26, 2024, subject to continued service.","Grant approved by Compensation Committee as inducement material to Dr. Guzman's employment as CMO and SVP of Medical Affairs.","Inducement award was granted outside ZyVersa's 2022 Equity Incentive Plan under Nasdaq Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-002761","json":"https://secwatch.observer/filing/0001493152-23-002761.json","markdown":"https://secwatch.observer/filing/0001493152-23-002761.md","text":"https://secwatch.observer/filing/0001493152-23-002761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223002761/0001493152-23-002761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223002761/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:24:06.624260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}